Wed.Sep 18, 2024

article thumbnail

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

Fierce Pharma

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. | Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. The crown jewel of the deal is undoubtedly Vtama, Dermavant’s steroid-free cream for plaque psoriasis, which is looking at a major expansion opportunity in eczema.

312
312
article thumbnail

The FDA Isn’t Blocking Medical Breakthroughs — Our Outdated Innovation Model Is

MedCity News

The current model of siloed, proprietary development is failing us. It’s slow, expensive, and often results in technologies that never see the light of day. What if, instead, we embraced an open-source approach to medical device innovation? The post The FDA Isn’t Blocking Medical Breakthroughs — Our Outdated Innovation Model Is appeared first on MedCity News.

Medical 121
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales

Fierce Pharma

This summer, GSK cut its yearly vaccine sales projection o | In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.

Sales 267
article thumbnail

Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary

MedCity News

By acquiring Dermavant, Organon gets Vtama, a drug approved for treating plaque psoriasis. An FDA decision for the topical cream in atopic dermatitis is expected by the end of 2024. The post Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary appeared first on MedCity News.

FDA 117
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease

Fierce Pharma

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 inhibitors have engaged in a spirited market battle, with one key differenc | Locked in a spirited market battle with GSK's Nucala, AstraZeneca's Fasenra is catching up with its IL-5 inhibitor rival as the FDA signed off on its use to treat the rare autoimmune condition of eosinophilic granulomatosis with polyangiitis.

FDA 261
article thumbnail

Millions are Taking a Drug that Falls Short of its Promise to Lower Risk of Heart Attack

MedCity News

While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a benefit of fenofibrates over and above statins in further reducing heart-related events. The post Millions are Taking a Drug that Falls Short of its Promise to Lower Risk of Heart Attack appeared first on MedCity News.

FDA 112

More Trending

article thumbnail

4 Things Startups Must Know to Achieve a Successful Tech Pilot

MedCity News

In recent years, providers have been increasingly conducting tech pilots to see which solutions can best improve their clinical and operation success. During a panel at MedCity News’ INVEST Digital Health conference in Dallas, healthcare leaders shared their insight on how startups can best serve their provider partners during these pilots. The post 4 Things Startups Must Know to Achieve a Successful Tech Pilot appeared first on MedCity News.

article thumbnail

Optimizing Patient Support Through Effective Information Governance: Balancing Risks and Rewards

Fierce Pharma

Authors: | Unlock the potential of patient support data with effective information governance. Manage risks, ensure compliance, and drive innovation for better patient outcomes.

article thumbnail

PBM strikes back at FTC over drug pricing report

pharmaphorum

PBM Express Scripts has sued the FTC, claiming its recent report on the sector's role in drug pricing is defamatory and should be retracted

124
124
article thumbnail

Enhancing Banking Sales Strategies For Future Growth

Integrity Solutions

Banking sales strategies are being redefined: Here’s how to pivot your customer relationships. While every industry grapples with the volatility of the economic environment and market conditions, banking and financial services organizations are dealing with specific challenges emerging from multiple disruptive forces: These challenges include: Maintaining an acceptable margin in a volatile yield curve market.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA expands Novartis’ Kisqali label to include early breast cancer patients

Pharmaceutical Technology

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.

Sales 98
article thumbnail

Lilly on alert as new Kisqali approval threatens Verzenio

pharmaphorum

Novartis' Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over rival Verzenio from Eli Lilly

FDA 105
article thumbnail

MHLW accepts GSK’s multiple myeloma treatment NDA for review

Pharmaceutical Technology

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

article thumbnail

NHS Trust to evaluate AI software for prostate cancer diagnosis

PharmaTimes

It is hoped that the tool will improve the diagnostic pathway and free up radiologists’ time

Medical 103
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

How Should Healthcare Startups Approach Employers? 3 Execs Weigh In

MedCity News

During a panel at the MedCity News INVEST Digital Health conference, three healthcare execs shared advice to startups on how to pitch to employers. They need to know their worth, understand the problem they’re solving, and think about issues globally. The post How Should Healthcare Startups Approach Employers? 3 Execs Weigh In appeared first on MedCity News.

article thumbnail

Getting IND ready — how companies can avoid common traps

PharmaVoice

Overpromising, overcommitting and neglecting CMC are a few of the pitfalls that cause sponsors to stumble when submitting a new drug application.

76
article thumbnail

Noom offers cut-price compounded GLP-1 drug for obesity

pharmaphorum

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.The bold move has been accompanied by a full-page ad in the Wall Street Journal explaining its reasoning, and claiming that the prices of GLP-1 drugs for weight loss are five times too high and need to be brought in line with levels in other countries.

59
article thumbnail

“Leave politics out of healthcare” – controversy swirls around BIOSECURE Act

Pharmaceutical Technology

At the Clinical Trial Supply West Coast 2024 conference, serial biotech entrepreneur Umar Hayat said science should be allowed to advance without political interference.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Title: Winning In Sales And Lessons From The Endoscopy Field With Jon Alwinson

Evolve Your Success

Unlock the secrets to excelling in medical sales! This episode promises to inspire and educate as we welcome Jon Alwinson, a veteran in the endoscopy sector, to share his remarkable career journey. Delve into Jon’s personal story, from the influence of his author father to his own four-year endeavor of writing a book aimed at guiding future medical sales reps.

Sales 52
article thumbnail

Validating Pharma 4.0 for Smart Manufacturing

PharmaTech

The drug manufacturing ecosystem Pharma 4.0, a term coined in 2017 by the International Society for Pharmaceutical Engineers, promises a revolution across drug discovery, manufacturing, and supply chain logistics, ensuring drugs are delivered precisely when needed, and improving overall patient care.

article thumbnail

Deerfield Group Bolsters Marketing, Communications Leadership with New Senior Appointments

PM360

Conshohocken, Pa., September 18, 2024 – Deerfield Group, one of the fastest-growing independent marketing and communications partners for healthcare and life science brands and companies, today announced two additions to its executive leadership team: Guy Varady will serve as Executive Vice President, Integrated Marketing, and Bob Josefsberg as Executive Vice President, Communications.

article thumbnail

FDA Approves Keytruda Plus Pemetrexed, Platinum Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

PharmExec

Approval was based on data from the IND.227/KEYNOTE-483 trial, which demonstrated a 21% reduction in the risk of death when Keytruda was added to chemotherapy in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

FDA 52
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA Approves New Dose Strength of Herceptin Biosimilar for HER2-Overexpressing Breast, Gastric Cancers

Pharmaceutical Commerce

Accord BioPharma's 420 mg strength Hercessi (trastuzumab-strf), a biosimilar to Herceptin, gains FDA approval to treat HER2-overexpressing breast cancer and gastric cancer.

FDA 52
article thumbnail

FDA Approves Fasenra for Eosinophilic Granulomatosis with Polyangiitis

PharmExec

Approval was based on results from the MANDARA Phase III trial, which demonstrated the superiority of Fansenra over Nucala in patients with eosinophilic granulomatosis with polyangiitis.

FDA 52
article thumbnail

FlyPharma Europe, Vienna – October 2024 conference

PharmaTimes

The conference will return to Vienna AirportCity on 23 to 24 October 2024

84
article thumbnail

Keytruda Demonstrates Superior Overall Survival vs. Yervoy in Advanced Melanoma

PharmExec

Ten-year data from the Phase III KEYNOTE-006 trial found that Keytruda produced a 34% ten-year overall survival rate compared to 23.6% for ipilimumab in patients with advanced melanoma.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA inspection backlog overseas threatens new drug approvals

PharmaVoice

The FDA’s backlog of overseas drug manufacturer inspections is still mounting — and new drugs could be delayed as a result.

FDA 59
article thumbnail

Braftovi Plus Mektovi Demonstrates Sustained Efficiency in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

PharmExec

Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an objective response rate of 75%.

article thumbnail

RFID Technology and the DSCSA: Paving the Way for a New Standard in Patient Care

Pharmacy Times

The Drug Supply Chain Security Act (DSCSA) will soon mandate end-to-end tracking of pharmaceuticals throughout the supply chain, with numerous benefits for health systems.

article thumbnail

Pharma Pulse: 9/18/24: How Drug Shortages Affect Pharmacovigilance, Long Strange Trip Continues for Psychedelics & more

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A